Regeneron Pharmaceuticals, Inc. Class Action Lawsuit - REGN

The filed complaint alleges that Regeneron Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Regeneron paid credit card fees to distributors on the condition that distributors did not charge, one of the Company’s primary products, Eylea customers more to use a credit card; (2) these payments subsidized the prices that customers paid when using credit cards to purchase Eylea; (3) as a result, Regeneron offered a price concession that lowered Eylea’s selling price; (4) because retina practices were sensitive to higher prices when using credit cards to purchase anti-VEGF medications, Regeneron’s price concessions provided a competitive advantage; (5) as a result of the foregoing, Regeneron misleadingly boosted reported Eylea sales; (6) by failing to report its payment of credit card fees as price concessions, Regeneron overstated the ASP reported to federal agencies, thereby violating the False Claims Act; and (7) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

In order to be eligible to join the REGN class action lawsuit, you must have incurred a loss on shares of Regeneron purchased during the class period listed above.

If you suffered a loss in Regeneron during the relevant time frame or pursuant to the relevant offering(s), you have until March 10, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.